ロード中...
Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database
BACKGROUND: The introduction of immune checkpoint inhibitors (ICIs) in clinical practice has brought significant benefits for patients. Seven ICIs are available in Europe: nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, cemiplimab, and ipilimumab. Despite their proven clinical efficacy...
保存先:
| 出版年: | Front Pharmacol |
|---|---|
| 主要な著者: | , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2020
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7295943/ https://ncbi.nlm.nih.gov/pubmed/32581796 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2020.00830 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|